Nothing Special   »   [go: up one dir, main page]

CL2011000117A1 - Anticuerpo de dominio (dab) que se unen a cd28 y previene la union de dicha proteina a cd80 y/o cd86; uso del anticuerpo para tratar una enfermedad inmune; y composicion farmaceutica que lo comprende. - Google Patents

Anticuerpo de dominio (dab) que se unen a cd28 y previene la union de dicha proteina a cd80 y/o cd86; uso del anticuerpo para tratar una enfermedad inmune; y composicion farmaceutica que lo comprende.

Info

Publication number
CL2011000117A1
CL2011000117A1 CL2011000117A CL2011000117A CL2011000117A1 CL 2011000117 A1 CL2011000117 A1 CL 2011000117A1 CL 2011000117 A CL2011000117 A CL 2011000117A CL 2011000117 A CL2011000117 A CL 2011000117A CL 2011000117 A1 CL2011000117 A1 CL 2011000117A1
Authority
CL
Chile
Prior art keywords
antibody
dab
treat
pharmaceutical composition
binding
Prior art date
Application number
CL2011000117A
Other languages
English (en)
Inventor
Murray Mckinnon
Steven G Nadler
Suzanne J Suchard
Brendan Classon
Steve Holmes
Olga Ignatovich
Christopher Plummer
Stev
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41226147&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000117(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CL2011000117A1 publication Critical patent/CL2011000117A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)

Abstract

Anticuerpo de dominio (DAB) que se une a CD28 y previene la unión de CD28 a CD80 y/o CD86; uso del anticuerpo para tratar una enfermedad inmune; composición farmacéutica que lo comprende.
CL2011000117A 2008-07-18 2011-01-18 Anticuerpo de dominio (dab) que se unen a cd28 y previene la union de dicha proteina a cd80 y/o cd86; uso del anticuerpo para tratar una enfermedad inmune; y composicion farmaceutica que lo comprende. CL2011000117A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8207808P 2008-07-18 2008-07-18
US16212109P 2009-03-20 2009-03-20

Publications (1)

Publication Number Publication Date
CL2011000117A1 true CL2011000117A1 (es) 2011-06-17

Family

ID=41226147

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2011000117A CL2011000117A1 (es) 2008-07-18 2011-01-18 Anticuerpo de dominio (dab) que se unen a cd28 y previene la union de dicha proteina a cd80 y/o cd86; uso del anticuerpo para tratar una enfermedad inmune; y composicion farmaceutica que lo comprende.
CL2012002428A CL2012002428A1 (es) 2008-07-18 2012-08-31 Anticurpos de dominio (dab) que se une a cd 28 e inhibe la union de cd28 a cd80 y/o cd86 y no reacciona en forma cruzada con ctla4; uso del anticuerpo para tratar una enfermedad inmune o relacionada con un injerto; composicion farmaceutica que lo comprende.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2012002428A CL2012002428A1 (es) 2008-07-18 2012-08-31 Anticurpos de dominio (dab) que se une a cd 28 e inhibe la union de cd28 a cd80 y/o cd86 y no reacciona en forma cruzada con ctla4; uso del anticuerpo para tratar una enfermedad inmune o relacionada con un injerto; composicion farmaceutica que lo comprende.

Country Status (30)

Country Link
US (6) US8168759B2 (es)
EP (2) EP2700651B1 (es)
JP (3) JP5675608B2 (es)
KR (2) KR101791372B1 (es)
CN (2) CN102159590A (es)
AR (1) AR072571A1 (es)
AU (1) AU2009270726B2 (es)
CA (1) CA2731220C (es)
CL (2) CL2011000117A1 (es)
CO (1) CO6341641A2 (es)
CY (1) CY1121796T1 (es)
DK (2) DK2700651T3 (es)
EA (1) EA024585B1 (es)
ES (2) ES2730727T3 (es)
HK (1) HK1155178A1 (es)
HR (2) HRP20160329T1 (es)
HU (2) HUE045249T2 (es)
IL (2) IL210413A (es)
LT (1) LT2700651T (es)
ME (1) ME02396B (es)
MX (1) MX2011000501A (es)
NZ (1) NZ590343A (es)
PE (2) PE20140852A1 (es)
PL (2) PL2700651T3 (es)
PT (2) PT2700651T (es)
RS (2) RS54675B1 (es)
SI (2) SI2321352T1 (es)
SM (2) SMT201900367T1 (es)
TW (2) TW201336510A (es)
WO (1) WO2010009391A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2778123T3 (es) 2005-05-18 2020-08-07 Ablynx Nv NanobodiesTM mejorados contra factor de necrosis tumoral alfa
US20110097339A1 (en) * 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
AR072571A1 (es) 2008-07-18 2010-09-08 Bristol Myers Squibb Co Composiciones monovalentes para union a cd28 y procedimientos de uso
RU2540010C2 (ru) * 2009-02-25 2015-01-27 Некстера АС НЕЗАВИСИМЫЙ ОТ СИГНАЛЬНОЙ ПОСЛЕДОВАТЕЛЬНОСТИ ФАГОВЫЙ ДИСПЛЕЙ НА БЕЛКЕ pIX
FR2951176A1 (fr) * 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
EP2361935A1 (en) * 2010-02-18 2011-08-31 TcL Pharma Anti-CD28 humanized antibodies
LT2536764T (lt) 2010-02-18 2018-10-25 Ose Immunotherapeutics Anti-cd28 humanizuoti antikūnai
RU2626537C2 (ru) 2010-06-08 2017-07-28 Дженентек, Инк. Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты
JP5768022B2 (ja) * 2012-03-19 2015-08-26 株式会社東芝 メモリコントローラ、記憶装置、誤り訂正装置および誤り訂正方法
WO2014120916A1 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
WO2015099165A1 (ja) * 2013-12-27 2015-07-02 中外製薬株式会社 等電点の低い抗体の精製方法
SG11201606521VA (en) 2014-03-19 2016-10-28 Bristol Myers Squibb Co Methods of treating transplant rejection using a domain antibody directed against cd40l
EP3191521A2 (en) 2014-09-12 2017-07-19 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
ES2783448T3 (es) * 2014-09-30 2020-09-17 Bristol Myers Squibb Co Métodos de tratamiento del lupus eritematoso sistémico utilizando un anticuerpo de dominio dirigido contra CD28
WO2017160975A1 (en) 2016-03-16 2017-09-21 Bristol-Myers Squibb Company Methods of diagnosing and treating lupus
EP3551046B1 (en) 2016-12-07 2023-07-19 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
JP7164544B2 (ja) 2017-04-11 2022-11-01 インヒブルクス インコーポレイテッド 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物およびそれを使用する方法
WO2019175885A1 (en) 2018-03-15 2019-09-19 Biond Biologics Ltd. Methods and compositions for decreasing soluble immune receptor cd28
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
EP3845652A4 (en) * 2018-06-22 2022-04-13 JUNTEN BIO Co., Ltd. ANTIBODIES FOR INDUCING IMMUNTOLERANCE, INDUCED LYMPHOCYTE AND THERAPEUTIC METHOD WITH CELL THERAPY AGENT USING INDUCED LYMPHOCYTE
EP3827019A1 (en) 2018-07-24 2021-06-02 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
KR102718808B1 (ko) 2018-08-03 2024-10-16 브리스톨-마이어스 스큅 컴퍼니 항-약물 항체를 검출하는 방법
AU2019383976A1 (en) 2018-11-19 2021-06-10 Biora Therapeutics, Inc. Methods and devices for treating a disease with biotherapeutics
US20220169732A1 (en) * 2019-03-14 2022-06-02 Biond Biologics Ltd. Small shedding blocking agents
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
CA3160216A1 (en) * 2019-12-02 2021-06-10 Motti HAKIM Use of mmp inhibition
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CA3168832A1 (en) * 2020-01-29 2021-08-05 Inhibrx, Inc. Cd28 single domain antibodies and multivalent and multispecific constructs thereof
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
US20230303699A1 (en) * 2020-08-04 2023-09-28 Exelixis, Inc. Pd-l1 binding agents and uses thereof
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
KR20240099157A (ko) * 2021-09-06 2024-06-28 비온드 바이오로직스 엘티디 Cd28 셰딩 차단제
WO2023215799A1 (en) * 2022-05-04 2023-11-09 Janux Therapeutics, Inc. Tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
WO2023215498A2 (en) * 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024077118A2 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839295A (en) 1984-06-08 1989-06-13 Pierce Chemical Company Measurement of protein using bicinchoninic acid
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
EP0814778B1 (de) 1995-03-10 2001-06-13 Roche Diagnostics GmbH Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung
PT859841E (pt) 1995-08-18 2002-11-29 Morphosys Ag Bibliotecas de proteinas/ (poli) peptidos
EP0988321A2 (en) 1997-06-20 2000-03-29 Innogenetics N.V. B7-binding molecules for treating immune diseases
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
EP1071400B1 (en) 1998-04-20 2004-11-03 Genzyme Corporation Drug delivery of proteins from polymeric blends
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
JP2003502024A (ja) 1999-05-14 2003-01-21 メディカル リサーチ カウンシル タンパク質骨格および単量体ポリペプチドを多量体化するためのその使用
US20020006403A1 (en) * 1999-12-14 2002-01-17 Xue-Zhong Yu CD28-specific antibody compositions for use in methods of immunosuppression
PT1345969E (pt) * 2000-12-26 2010-11-17 Inst Nat Sante Rech Med Anticorpos anti-cd28
WO2002066059A2 (en) 2001-02-16 2002-08-29 Genetics Institute, Llc Agents that specifically block cd28-mediated signaling and uses therefor
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
AU2002319402B2 (en) 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
AU2002319544B2 (en) 2001-08-10 2008-07-10 Aberdeen University Antigen binding domains from fish
US20050130124A1 (en) 2001-10-05 2005-06-16 Wiersma Erik J. Phagemid display system
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
DE10156482A1 (de) * 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
SI1517921T1 (sl) 2002-06-28 2006-10-31 Domantis Ltd Dvojno-specificni ligandi z zvisano serumsko razpolovno dobo
JP2006524036A (ja) 2002-11-08 2006-10-26 アブリンクス エン．ヴェー． 腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用
JP2006523090A (ja) 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
EP1629012B1 (en) 2003-05-31 2018-11-28 Amgen Research (Munich) GmbH Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
CN100376599C (zh) * 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
UA94213C2 (ru) * 2004-09-17 2011-04-26 Домантис Лимитед Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания
GB0614093D0 (en) 2006-07-14 2006-08-23 Bae Systems Plc Deployable antenna system
WO2008071447A2 (en) * 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
AR072571A1 (es) 2008-07-18 2010-09-08 Bristol Myers Squibb Co Composiciones monovalentes para union a cd28 y procedimientos de uso
MX2011001624A (es) 2008-08-21 2011-03-28 Octapharma Ag Factor viii y ix humano producido en forma recombinante.
SG11201606521VA (en) * 2014-03-19 2016-10-28 Bristol Myers Squibb Co Methods of treating transplant rejection using a domain antibody directed against cd40l
ES2783448T3 (es) * 2014-09-30 2020-09-17 Bristol Myers Squibb Co Métodos de tratamiento del lupus eritematoso sistémico utilizando un anticuerpo de dominio dirigido contra CD28

Also Published As

Publication number Publication date
CO6341641A2 (es) 2011-11-21
RS54675B1 (en) 2016-08-31
EP2700651A1 (en) 2014-02-26
DK2700651T3 (da) 2019-07-22
TW201336510A (zh) 2013-09-16
EP2700651B1 (en) 2019-04-10
US8168759B2 (en) 2012-05-01
JP2011528551A (ja) 2011-11-24
HK1155178A1 (zh) 2012-05-11
KR20160113322A (ko) 2016-09-28
ES2730727T3 (es) 2019-11-12
US9908937B2 (en) 2018-03-06
HRP20160329T1 (hr) 2016-04-22
DK2321352T3 (en) 2016-04-04
AU2009270726A1 (en) 2010-01-21
CN102159590A (zh) 2011-08-17
SMT201900367T1 (it) 2019-09-09
JP2015120695A (ja) 2015-07-02
IL251320A0 (en) 2017-05-29
CY1121796T1 (el) 2020-07-31
US20210047414A1 (en) 2021-02-18
JP6058833B2 (ja) 2017-01-11
AR072571A1 (es) 2010-09-08
KR101660057B1 (ko) 2016-09-26
PL2700651T3 (pl) 2019-09-30
PE20110385A1 (es) 2011-06-22
US20150299321A1 (en) 2015-10-22
KR101791372B1 (ko) 2017-10-27
ES2562629T3 (es) 2016-03-07
US9085629B2 (en) 2015-07-21
IL210413A (en) 2017-04-30
JP2016063830A (ja) 2016-04-28
SI2321352T1 (sl) 2016-04-29
CL2012002428A1 (es) 2013-01-11
US8454959B2 (en) 2013-06-04
RS58904B1 (sr) 2019-08-30
IL251320B (en) 2019-01-31
HUE029982T2 (en) 2017-04-28
EA201100239A1 (ru) 2011-10-31
US20120201814A1 (en) 2012-08-09
CN105936648A (zh) 2016-09-14
AU2009270726B2 (en) 2015-07-09
US20130109846A1 (en) 2013-05-02
EP2321352B1 (en) 2016-01-06
HUE045249T2 (hu) 2019-12-30
TWI450725B (zh) 2014-09-01
US20100028354A1 (en) 2010-02-04
SMT201600090B (it) 2016-04-29
EA024585B1 (ru) 2016-10-31
SI2700651T1 (sl) 2019-08-30
PT2700651T (pt) 2019-06-19
IL210413A0 (en) 2011-03-31
WO2010009391A1 (en) 2010-01-21
LT2700651T (lt) 2019-06-25
CN105936648B (zh) 2020-06-16
US12012452B2 (en) 2024-06-18
MX2011000501A (es) 2011-05-23
PT2321352E (pt) 2016-03-18
ME02396B (me) 2016-08-31
PE20140852A1 (es) 2014-07-14
EP2321352A1 (en) 2011-05-18
KR20110041527A (ko) 2011-04-21
HRP20190966T1 (hr) 2019-07-26
JP5675608B2 (ja) 2015-02-25
TW201006494A (en) 2010-02-16
NZ590343A (en) 2012-10-26
CA2731220A1 (en) 2010-01-21
US20180142023A1 (en) 2018-05-24
CA2731220C (en) 2017-10-10
PL2321352T3 (pl) 2016-06-30
US10919965B2 (en) 2021-02-16
JP5876134B2 (ja) 2016-03-02

Similar Documents

Publication Publication Date Title
CL2011000117A1 (es) Anticuerpo de dominio (dab) que se unen a cd28 y previene la union de dicha proteina a cd80 y/o cd86; uso del anticuerpo para tratar una enfermedad inmune; y composicion farmaceutica que lo comprende.
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
CL2018003520A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco.
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
HN2011000357A (es) Composiciones y metodos para anticuerpos que que se dirigen a la proteina de complemento c5
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
GT201700102A (es) Conjugados de anticuerpo-fármaco
CL2013000843A1 (es) Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso.
CR20120506A (es) PROTEÍNAS QUE SE UNEN AL TNF-a
CR20140585A (es) Proteinas de union a antigeno st2
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112012013876A2 (pt) proteínas de ligação do antígeno humano que ligam o seu b-klotho, receptores de fgf e seus complexos
MX2011011754A (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b.
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
CO6680656A2 (es) Anticuerpos para metaloproteinasa -9 de matriz
DOP2014000083A (es) Inmunoenlazadores dirigidos contra el tnf
BR112017000671A2 (pt) moléculas com especificidade para cd79 e cd22
CY1114904T1 (el) Prlr-ειδικο αντισωμα και χρησεις αυτου
CY1116488T1 (el) Αντισωματα anti-προπερδινης
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
MX2017009680A (es) Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d).
AR093620A1 (es) Anticuerpos bmp-6
PH12019500677A1 (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3